BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/16/2020 11:58:14 PM | Browse: 740 | Download: 1097
 |
Received |
|
2019-11-01 05:43 |
|
Peer-Review Started |
|
2019-11-01 05:43 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2019-11-21 01:04 |
|
Revised |
|
2019-12-06 15:55 |
|
Second Decision |
|
2020-02-20 10:25 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-02-23 22:42 |
|
Articles in Press |
|
2020-02-23 22:42 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-03-13 08:39 |
|
Publish the Manuscript Online |
|
2020-03-16 23:58 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Efficacy, patterns of use and cost of Pertuzumab in the treatment of HER2+ metastatic breast cancer in Singapore: The National Cancer Centre Singapore experience
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sylwan Rahardja, Ryan Ying Cong Tan, Rehena Sultana, Fun Loon Leong and Elaine Hsuen Lim |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Sylwan Rahardja, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, Singapore 119228, Singapore. sylwanrahardja@gmail.com |
| Key Words |
Pertuzumab; Chemotherapy; Metastatic breast cancer; Treatment cost; ; |
| Core Tip |
Pertuzumab is a humanized anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody found in a Phase III clinical trial to significantly improve median survival in HER2 positive metastatic breast cancer when used in combination with a taxane and Trastuzumab, and its clinical efficacy has transformed the therapeutic landscape of HER2-positive breast cancer. In our study, there was a statistically significant difference in the median overall survival between Pertuzumab and non-Pertuzumab groups [51.5 (95%CI: 35.8–60.0) vs 32.9 (95%CI: 28.1–37.5) mo; P = 0.0128] while the rate of grade 3 cardiotoxicity was low (4.88%). However, costs remain high. |
| Publish Date |
2020-03-16 23:58 |
| Citation |
Rahardja S, Tan RYC, Sultana R, Leong FL, Lim EH. Efficacy, patterns of use and cost of Pertuzumab in the treatment of HER2+ metastatic breast cancer in Singapore: The National Cancer Centre Singapore experience. World J Clin Oncol 2020; 11(3): 143-151 |
| URL |
https://www.wjgnet.com/2218-4333/full/v11/i3/143.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v11.i3.143 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
